Pilot Study of a Prophylactic Neopeptide Vaccine in Advanced ALK+ NSCLC

Conditions:   NSCLC Stage IV;   ALK Fusion Protein Expression Intervention:   Biological: Peptide vaccine Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials